Nextera AS
www.nextera.noNextera is a drug and target discovery company offering a unique and novel approach for improved therapeutic intervention in the major disease areas autoimmunity, chronic inflammatory disorders and cancer. Our approach is to modulate the disease at the core of the escalating immune cascade translating to disease-specific treatment without compromising systemic immunity. Our strategy is to discover new targets and develop cognate drugs together with partners. We want to address complex diseases and jointly develop therapies in major indications that today seem difficult to treat. It all starts and ends with the patient – focused onto to diseased tissue and the underlying immune repertoires, Nextera brings the unique ability to decipher clinical material with the outlook of subsequent intervention.
Read moreNextera is a drug and target discovery company offering a unique and novel approach for improved therapeutic intervention in the major disease areas autoimmunity, chronic inflammatory disorders and cancer. Our approach is to modulate the disease at the core of the escalating immune cascade translating to disease-specific treatment without compromising systemic immunity. Our strategy is to discover new targets and develop cognate drugs together with partners. We want to address complex diseases and jointly develop therapies in major indications that today seem difficult to treat. It all starts and ends with the patient – focused onto to diseased tissue and the underlying immune repertoires, Nextera brings the unique ability to decipher clinical material with the outlook of subsequent intervention.
Read moreCountry
City (Headquarters)
Oslo
Industry
Employees
11-50
Founded
2009
Social
Employees statistics
View all employeesPotential Decision Makers
Chief Executive Officer
Email ****** @****.comPhone (***) ****-****Board Member
Email ****** @****.comPhone (***) ****-****Chief Executive Officer
Email ****** @****.comPhone (***) ****-****Chairman and Co - Founder
Email ****** @****.comPhone (***) ****-****
Technologies
(12)